Genetic polymorphism of vitamin D receptors and plasminogen activator inhibitor-1 and osteonecrosis risk in childhood acute lymphoblastic leukemia
- Resource Type
- Authors
- Nermin Raafat; Laila M. Sherief; Wesam A. Mokhtar; Khaled M. El-Gerby; Hosam E. Salah; Naglaa M. Kamal; Elhamy R. Abdelkhalek; Basma K. Soliman; Mohamed Beshir; Heba M. El-Sayed; Ghada A. Mokhtar; Marwa Zakaria
- Source
- Molecular Genetics & Genomic Medicine
Molecular Genetics & Genomic Medicine, Vol 9, Iss 7, Pp n/a-n/a (2021)
- Subject
- 0301 basic medicine
Male
medicine.medical_specialty
Adolescent
PAI‐1
QH426-470
030105 genetics & heredity
Gastroenterology
Calcitriol receptor
Polymorphism, Single Nucleotide
polymorphism
03 medical and health sciences
chemistry.chemical_compound
Polymorphism (computer science)
Internal medicine
Genotype
Plasminogen Activator Inhibitor 1
Genetics
Vitamin D and neurology
medicine
Humans
Risk factor
Child
Molecular Biology
Childhood Acute Lymphoblastic Leukemia
Genetics (clinical)
VDR
business.industry
osteonecrosis
Original Articles
Precursor Cell Lymphoblastic Leukemia-Lymphoma
030104 developmental biology
pediatric
chemistry
Plasminogen activator inhibitor-1
Child, Preschool
Receptors, Calcitriol
Female
Original Article
Gene polymorphism
business
ALL
- Language
- ISSN
- 2324-9269
Background Osteonecrosis (ON) is one of the major therapy‐related complications in childhood acute lymphoblastic leukemia (ALL). The purpose of the current study is to assess the frequency of ON in children with ALL and to detect whether polymorphisms in vitamin D receptor gene (VDR) and plasminogen activator inhibitor‐1 (PAI‐1) gene can affect the risk of ON. Patients and Methods Nighty‐six ALL children were enrolled. Serum 25‐hydroxyvitamin D 25(OH)D levels were performed in addition to the detection of polymorphisms in PAI‐1and VDR genes by polymerase chain reaction. Results Ten out of 96 patients had ON (four males and six females aged above 10 years) and had an insufficient level of 25(OH)D. Fifty‐two percent of patients had PAI‐1 GG genotype while 48% had PAI‐1 GA genotype. PAI‐1 polymorphism was detected in 60% of all ON cases. The frequencies of VDR genotypes were CT (56.3%), CC (39.6%), and TT (4.2%). Osteonecrosis was found in eight patients with CC genotype and in two patients with CT genotype. Conclusion Osteonecrosis can develop early during the therapy of ALL. Older age and insufficient level of 25(OH)D were considered important risk factor for the development of osteonecrosis. PAT‐1 and VDR gene polymorphism may be a genetic risk factor in its pathogenesis.
Osteonecrosis can develop early during the therapy of ALL. Older age and insufficient level of 25(OH)D were considered an important risk factor for the development of osteonecrosis. PAT‐1 and VDR gene polymorphism may be a genetic risk factor in its pathogenesis.